Madrigal Pharmaceuticals, Inc. (MDGL)
541.08
-1.53
(-0.28%)
USD |
NASDAQ |
Sep 04, 16:00
540.70
-0.38
(-0.07%)
After-Hours: 20:00
Madrigal Pharmaceuticals Research and Development Expense (Quarterly) : 90.80M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 90.80M |
| March 31, 2026 | 108.31M |
| December 31, 2025 | 115.88M |
| September 30, 2025 | 173.65M |
| June 30, 2025 | 53.70M |
| March 31, 2025 | 43.79M |
| December 31, 2024 | 25.28M |
| September 30, 2024 | 68.44M |
| June 30, 2024 | 70.82M |
| March 31, 2024 | 71.07M |
| December 31, 2023 | 70.50M |
| September 30, 2023 | 70.82M |
| June 30, 2023 | 68.48M |
| March 31, 2023 | 62.03M |
| December 31, 2022 | 70.61M |
| September 30, 2022 | 68.27M |
| June 30, 2022 | 58.50M |
| March 31, 2022 | 47.93M |
| December 31, 2021 | 52.89M |
| September 30, 2021 | 54.87M |
| June 30, 2021 | 51.63M |
| March 31, 2021 | 45.77M |
| December 31, 2020 | 53.43M |
| September 30, 2020 | 53.29M |
| June 30, 2020 | 44.69M |
| Date | Value |
|---|---|
| March 31, 2020 | 33.40M |
| December 31, 2019 | 24.91M |
| September 30, 2019 | 19.45M |
| June 30, 2019 | 15.59M |
| March 31, 2019 | 12.37M |
| December 31, 2018 | 8.871M |
| September 30, 2018 | 6.211M |
| June 30, 2018 | 5.109M |
| March 31, 2018 | 5.198M |
| December 31, 2017 | 6.512M |
| September 30, 2017 | 6.682M |
| June 30, 2017 | 6.816M |
| March 31, 2017 | 4.38M |
| December 31, 2016 | 5.524M |
| September 30, 2016 | 7.805M |
| June 30, 2016 | 2.088M |
| March 31, 2016 | 0.516M |
| December 31, 2015 | 0.7732M |
| September 30, 2015 | 0.6826M |
| June 30, 2015 | 16.38M |
| March 31, 2015 | 16.18M |
| December 31, 2014 | 15.65M |
| September 30, 2014 | 16.21M |
| June 30, 2014 | 18.76M |
| March 31, 2014 | 17.58M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 413.13M |
| Exelixis, Inc. | 211.99M |
| United Therapeutics Corp. | 146.30M |
| Karyopharm Therapeutics, Inc. | 28.96M |
| ACADIA Pharmaceuticals, Inc. | 81.56M |